Broadridge Financial Solutions Inc (BR) Stock News

Rosen Law Firm has filed class action lawsuits against Black Rock Coffee Bar, Inc. (BRCB), GeneDx Holdings Corp. (WGS), and SES AI Corporation (SES) on behalf of investors who purchased securities during specified periods. The lawsuits allege that defendants made materially false and misleading statements regarding business operations and prospects. Black Rock Coffee is specifically accused of failing to disclose that new store openings caused cannibalization of existing revenue and overstating its expansion strategy effectiveness.

TruBridge, Inc. (NASDAQ: TBRG) is facing a potential securities class action lawsuit after disclosing accounting errors in previously published financial statements. The company identified errors in revenue recognition, contract costs, stock-based compensation, and capitalized software development expenses across multiple fiscal periods. Following the announcement on March 17, 2026, the stock declined 10.5% to $15.75 per share. Rosen Law Firm is investigating claims on behalf of affected shareholders.

Brodsky & Smith law firm is investigating four merger transactions to determine whether company boards breached fiduciary duties to shareholders. The investigations concern AstroNova (being acquired by Arcline for $29.00/share), Open Lending (being acquired by ANV Group for $3.15/share), Huntsman (merging with Olin in a stock exchange), and Standard BioTools (being acquired by Treeline Biosciences). The firm is seeking shareholders to discuss whether fair processes were conducted and fair value provided.

The Rosen Law Firm is investigating potential securities claims against TruBridge, Inc. after the company filed a late filing notification on March 17, 2026, disclosing material errors in previously issued financial statements for 2023-2025. The errors involved revenue recognition, stock-based compensation, and capitalized software development expenses. TruBridge's stock fell 10.5% on the announcement. Investors who suffered losses are encouraged to join a prospective class action lawsuit.

Sleep Number Corp. shares plunged 31% in after-hours trading after Nasdaq announced plans to delist the company following its Chapter 11 bankruptcy filing on June 12. Trading will be suspended on June 23, 2026. The stock has declined 94.57% over the past 12 months, and common shareholders face uncertainty about recovery during bankruptcy proceedings.

Halper Sadeh LLC, an investor rights law firm, is investigating three companies for potential violations of federal securities laws and breaches of fiduciary duties. The investigations concern Simulations Plus' sale to Altaris for $18.50 per share, Roku's sale to Fox Corporation for $96.00 cash plus 0.9693 Fox shares per share, and TruBridge's sale to Inventurus Knowledge Solutions for $26.25 per share. The firm is seeking increased consideration, additional disclosures, and other relief on behalf of shareholders.

Brodsky & Smith law firm is investigating four merger transactions to determine whether company boards breached fiduciary duties by failing to conduct fair processes and provide fair value to shareholders. The investigations involve Simulations Plus ($18.50/share), Roku ($160.00/share), TruBridge ($26.25/share), and Organon ($14.00/share).

The article compares CBRE Group and Newmark Group as commercial real estate investment options for 2026. CBRE is a global industry giant with $40.6B in revenue and Fortune 100 clients, while Newmark is a smaller, faster-growing challenger with 20.3% revenue growth and a 1.6% dividend yield. Despite CBRE's recent stock decline following a pension-related charge, the analysis concludes that Newmark is the better buy due to its lower valuation, higher growth rate, and dividend income.

Rosen Law Firm is investigating potential securities claims against TruBridge, Inc. after the company disclosed material errors in its financial statements on March 17, 2026. TruBridge identified out-of-period errors in previously issued consolidated financial statements for 2024 and 2023, as well as quarterly statements for 2025, relating to revenue recognition, stock-based compensation, and capitalized software development expenses. The disclosure triggered a 10.5% stock price decline. The firm is preparing a class action lawsuit to recover investor losses.

BRT Apartments Corp. (NYSE:BRT) announced a quarterly dividend of $0.25 per share, payable on July 9, 2026, to shareholders of record as of June 25, 2026. The REIT owns or has interests in 31 multifamily properties with 8,311 units across 11 states.

The Rosen Law Firm is investigating potential securities claims against TruBridge, Inc. after the company disclosed material errors in its previously issued financial statements for fiscal years 2023-2025. The errors relate to revenue recognition, stock-based compensation, and capitalized software development expenses. Following the announcement on March 17, 2026, TruBridge's stock fell 10.5% to $15.75 per share. Investors who suffered losses are encouraged to join a prospective class action lawsuit.

Pomerantz LLP is investigating potential securities fraud claims against Sleep Number Corporation following the company's May 12, 2026 earnings announcement. Sleep Number reported a loss of $2.19 per share (missing estimates by $1.72), revenue of $318.99 million (down 18.9% year-over-year), and suspended financial guidance. The stock fell 22.45% to $1.90 per share on the news.

KBR announced that its Mission Technology Solutions business has been awarded a $95 million Digital Engineering and Enterprise Decision Support (DEEDS) contract with the U.S. Space Force. The five-year cost-plus-fixed-fee contract will advance digital engineering capabilities for space systems development and warfighting technologies, with work performed at Kirtland Air Force Base in New Mexico.

Axsome Therapeutics announced presentations of new clinical data for SYMBRAVO® (meloxicam and rizatriptan) at the American Headache Society's 68th Annual Scientific Meeting in Orlando, FL (June 4-7, 2026). Four poster presentations will showcase efficacy, safety, and comparative effectiveness data from Phase 3 trials MOMENTUM and MOVEMENT, as well as network meta-analysis comparing SYMBRAVO to gepants for acute migraine treatment.

TruBridge, Inc. (NASDAQ: TBRG) filed a late filing notification on March 17, 2026, revealing material errors in previously issued financial statements for fiscal years 2023-2025. The errors involved revenue recognition, stock-based compensation, and capitalized software development expenses. The disclosure triggered a 10.5% stock price decline. The Rosen Law Firm is preparing a class action lawsuit to recover investor losses.

KBR won an $8 billion Antarctica contract from the U.S. National Science Foundation with a 20-year performance period, yet the stock fell 1.09% on the news. Despite the significant contract award expected to provide long-term revenue stability, KBR shares remain under pressure due to broader market bearish sentiment, weak growth momentum, and a 31.99% decline over the past 12 months.

KBR has been awarded an $8 billion, 20-year Antarctic Science and Engineering Support Contract (ASESC) by the U.S. National Science Foundation. The contract involves providing full-scale operations, maintenance, logistics, science support, IT, AI, and cybersecurity services across three U.S. Antarctic stations and research sites.

Law firm Bragar Eagel & Squire is investigating Black Rock Coffee Bar, Inc. (NASDAQ: BRCB) for potential federal securities law violations following the company's disappointing Q1 2026 earnings report. Black Rock missed consensus estimates on both earnings per share ($0.02 vs. $0.03 expected) and revenue ($55.5M vs. $56.64M expected), causing the stock to plummet 30.26% from $10.97 to $7.65 per share on May 13, 2026, just eight months after its IPO at $20.00 per share.

Law firm Wolf Haldenstein Adler Freeman & Herz LLP is investigating Sleep Number Corporation for potential securities fraud. The investigation follows Sleep Number's May 12, 2026 earnings announcement where the company missed consensus estimates significantly, reporting a GAAP loss of $2.19 per share versus expected earnings, and revenue of $318.99 million versus $320.72 million expected. The company also suspended financial guidance, causing its stock to plummet 22.45% to $1.90 per share.

Law firm Kirby McInerney LLP is investigating Black Rock Coffee Bar, Inc. for potential federal securities law violations following the company's May 2026 earnings miss and significant stock price decline. The company reported Q1 2026 GAAP EPS of $0.02 and revenue of $55.5 million, both below consensus estimates, and disclosed cannibalization issues from new store openings in Phoenix. The stock fell approximately 30% from $10.97 to $7.65 per share on the news.

KBR announced that NorSAF has selected its proprietary PureSAF® technology for a new sustainable aviation fuel (SAF) and e-SAF production plant in the Baltics, expected to produce 100,000 tons annually starting in 2030. The project aligns with EU's ReFuelEU Aviation Regulation mandating 6% SAF blending by 2030, rising to 70% by 2050.

Highlights Revenues of $2,391.8 million, an increase of 29.5% compared to last year, driven by higher ORV and PWC shipments, as well as favourable ORV product mix; Net income of $127.3 million, a decrease of 20.9% compared to last year; Normalized EBITDA [1] of $334.4 million, an increase of 66.5% compared to last year; Normalized diluted earnings per share [1][2] of $1.83, an increase of $1.36 per share, and diluted earnings per share [2] of $1.73, a decrease of $0.46 per share, compared to last year; North American Powersports retail sales decreased by 7% compared to last year, mainly due to a strong end-of-season in Snowmobile last year; Market share gains in North America for ORV; Issuing a revised full-year guidance, incorporating incremental tariff cost net of mitigation measures, with revenues between $9.1 and $9.4 billion, and Normalized diluted earnings per share [1][2] between $3.00 and $3.50. VALCOURT, QC , May 28, 2026 /CNW/ - BRP Inc. (TSX: DOO ) (NASDAQ: DOO ) today reported its financial results for the three-month period ended April 30, 2026. All financial information is in Canadian dollars unless otherwise noted. The complete financial results are available on SEDAR+ and EDGAR as well as in the section Quarterly Reports of BRP's website. "We delivered Q1 financial results above expectations, driven by higher volumes, disciplined cost management, strong overall execution and a more favourable promotional environment. We also sustained our solid retail momentum across key ORV segments, as new product introductions in the second half of last year contributed to additional market share gains," said Denis Le Vot, President and CEO of BRP. "As tariff policies shifted significantly during the quarter, our teams moved quickly to define mitigation measures to reduce their impact. Looking ahead, we are focused on navigating these headwinds while also protecting

Law firm Kirby McInerney LLP is investigating Black Rock Coffee Bar, Inc. for potential federal securities law violations following the company's May 2026 earnings miss and significant stock price decline. The company reported Q1 2026 GAAP EPS of $0.02 and revenue of $55.5 million, both below consensus estimates, and disclosed cannibalization issues from new store openings in Phoenix. The stock fell approximately 30% from $10.97 to $7.65 per share on the news.

Verra Mobility's stock fell over 40% after Avis Budget Group terminated a major commercial services agreement. The company reduced its 2026 guidance following the termination. Block & Leviton is investigating potential securities law violations, claiming management had previously assured investors of a successful renewal and expected resolution in the first half of 2026.

Pomerantz Law Firm has filed class action lawsuits against ImmunityBio, Inc., New Era Energy & Digital, Inc., and Vital Farms, Inc. for alleged securities fraud and unlawful business practices. The primary case involves ImmunityBio, which faced an FDA warning letter on March 24, 2026, for continuing to promote its bladder-cancer drug Anktiva in a misleading manner despite previous warnings. The disclosure triggered a 21.12% stock price decline. Investors have until May 26, 2026, to request Lead Plaintiff status.

BioRestorative Therapies announced completion of dosing in its Phase 2 clinical trial for BRTX-100, treating 99 patients with chronic lumbar disc disease. The randomized, double-blind, sham-controlled study has advanced to blinded follow-up with topline safety and efficacy data expected in Q2 2027. The company received FDA alignment on Phase 3 development pathway following a Type B meeting, with no clinical safety concerns raised.

TruBridge, Inc. filed a late filing notification on March 17, 2026, revealing material errors in previously issued financial statements for fiscal years 2023-2025, including misstatements in revenue recognition, stock-based compensation, and software development expenses. The disclosure triggered a 10.5% stock price decline. The Rosen Law Firm is investigating potential securities claims on behalf of shareholders.

Rosen Law Firm reminds ImmunityBio investors of the May 26, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that defendants made false and misleading statements about Anktiva's capabilities and ImmunityBio's business operations. Investors who purchased securities between January 19, 2026 and March 24, 2026 may be entitled to compensation.

The Schall Law Firm is investigating Sleep Number Corporation for potential securities law violations following the company's Q1 2026 earnings report on May 12, 2026. Sleep Number's earnings per share fell 18.9% year-over-year, missed consensus estimates, and the company suspended its financial guidance, resulting in a 22.45% stock price decline. The firm is seeking shareholders who suffered losses to participate in the investigation.

The Schall Law Firm is seeking investors who purchased ImmunityBio securities between January 19, 2026 and March 24, 2026 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements about its Anktiva drug capabilities, causing investor losses when the truth was revealed.